DL-Mepivacaine
DL-Mepivacaine Brand names, DL-Mepivacaine Analogs
DL-Mepivacaine Brand Names Mixture
- No information avaliable
DL-Mepivacaine Chemical_Formula
C4H11N5
DL-Mepivacaine RX_link
http://www.rxlist.com/cgi/generic4/glumetza.htm
DL-Mepivacaine fda sheet
DL-Mepivacaine msds (material safety sheet)
DL-Mepivacaine Synthesis Reference
No information avaliable
DL-Mepivacaine Molecular Weight
129.164 g/mol
DL-Mepivacaine Melting Point
223-226 oC
DL-Mepivacaine H2O Solubility
Freely soluble as HCl salt
DL-Mepivacaine State
Solid
DL-Mepivacaine LogP
-0.267
DL-Mepivacaine Dosage Forms
Extended release tablet (500 mg or 1000 mg)
DL-Mepivacaine Indication
For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.
DL-Mepivacaine Pharmacology
Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.
DL-Mepivacaine Absorption
Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.
DL-Mepivacaine side effects and Toxicity
Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.
DL-Mepivacaine Patient Information
DL-Mepivacaine Organisms Affected
Humans and other mammals
